|
|
 |
|
Viewing report
|
|
|
|
Therapeutic Proteins: Strategic Market Analysis and Forecasts to 2010
Datamonitor, Aug 2002
The therapeutic protein market grew by 14% in 2001 and is forecast to achieve sales of over $57bn by 2010. Growth to date has been dominated by sales of erythropoietins and insulins, while future growth will reflect the increasing significance of monoclonal antibodies and therapeutic vaccines. However, there are a number of critical issues that companies must overcome to be successful, notably the threat of biogenerics and the imminent shortfall in biologics manufacturing capacity.Analysis of global and 7 country (US, Japan, France, Germany, Italy, Spain, UK) product and class sales across 13 therapeutic protein classesIn-depth evaluation of the commercial potential of the therapeutic protein R&D pipelineForecast year-on-year sales for all major products and classes to 2010Recommendations for managing the emerging threat from biogenerics, including a timeline of impact, key companies involved and products most at riskAnalysis of the forthcoming shortfall in manufacturing capacity and its implications for future market growthThe strategies adopted by Pfizer and Aventis to gain regulatory approval and overcome the safety issues facing the first non-injectable insulin Exubera, will set a precedent for other companies with earlier stage inhalable and oral insulins.The intensive, high volume manufacturing process for monoclonal antibodies has resulted in drugs having to command premium prices, limiting their market penetration. However, with over 35 products in phase II development, competition within the monoclonal antibody class will strengthen as more products make it through to market by 2010.Over $13.5bn of the $27bn therapeutic proteins market in 2001 will be exposed to generic competition by the end of 2005.Optimize penetration with comprehensive knowledge of the sales performance, growth drivers and country-specific factors surrounding competing proteinsIdentify key pipeline products for in-licensing opportunities and areas of unmet needMaximize your product’s potential by implementing optimal biogeneric defense strategiesTarget resources more effectively to ensure that your required manufacturing capacity is available
Customers who bought this item also bought
Therapeutic Monoclonal Antibodies Markets
Competitor Analysis: Biogenerics & Therapeutic Proteins
Br Malls Participacoes Sa
Br. Holdings Corporation
The Therapeutic Proteins Outlook To 2007: An Analysis Of Leading Products And Late-Stage Pipeline Developments
Monoclonal Antibodies 2007: Competitive Landscape & Pipeline Insight
Monoclonal Antibodies Report: 2008 Update
Monoclonal Antibodies Report Part I
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
PharmaVitae 2001: Inhale Therapeutic Systems
U.S. Therapeutic Monoclonal Antibodies Markets
Market Dynamics 2001: Anti-Cancer Innovatives Series
|
|
|
|
